Trial Profile
A Multicenter, Retrospective Study Assessing Real-world Utilization and Effectiveness of Elbasvir/grazoprevir (EBR/GZR) in Adult Patients with Chronic Hepatitis C in Canada
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 May 2018
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms Z-PROFILE
- 16 May 2018 New trial record
- 14 Apr 2018 Interim analysis results (n=267) of patients from 13 sites, presented at The International Liver Congress 2018.